The COVID-19 pandemic was a watershed moment for our country. While the pharmaceutical sector was robust, it lacked the capacity to produce specialised molecular components at scale. At the start of 2020, nearly all of the 20-plus reagents and enzymes required for making the vaccine kits were imported. Supplies were also vulnerable as the countries where these came from struggled with their own outbreaks.
The pandemic brought to light bottlenecks in the supply chains that support research, development, and manufacturing in the biotechnology and health sectors. Vast arrays of specialty reagents are required to drive innovation in new therapeutics and to make accurate diagnostic kits.
Leave a Reply